EU: The European Public Prosecutor’s Office (EPPO) said it has opened investigation into the EU’s procurement of COVID-19 vaccines. The announcement follows recent attention on alleged text exchanges between Pfizer CEO Albert Bourla and European Commission President Ursula von der Leyen in the lead-up to a procurement contract for up to 1.8 billion doses of the Pfizer/BioNTech vaccine Comirnaty.
The EPPO didn’t specify who or which specific deal is under investigation but said it comes after “extremely high public interest.”
“This exceptional confirmation comes in light of the extremely high public interest. No other details will be made public at this stage,” the institution’s statement reads.
The European Commission has so far concluded contracts for up to 4.2 billion doses of vaccines against COVID-19, according to data on the Commission’s website. By September 7, 2022, 1.7 billion doses have been delivered. More than half of the 4.2 billion doses bought or reserved by the EU are supplied by the American-German joint venture Pfizer-BioNTech.
This happened after the journalistic investigation on Gates’ NGO lobbying to EU and US politicians and officials.
Number of doses for which contracts were signed:
- BioNTech and Pfizer – 2.4 billion doses
- Moderna – 460 million doses
- AstraZeneca – 400 million doses
- Johnson & Johnson – 400 million doses
- Novavax – 200 million doses
- Valneva – 1.2 million doses
- Sanofi-GSK – 300 milioane doze
- HIPRA Human Health – 250 million doses
Key provisions of the contracts, especially prices, are confidential, an aspect that has been criticized by members of the European Parliament and NGOs.
Following an article published by the New York Times in April 2021 in which it was written that the head of the Commission had exchanged text messages with Albert Bourla in the context of negotiations regarding a contract for the purchase of vaccines, a journalist asked the Commission for access to those messages and other documents related to these discussions.
The EU executive, which was mandated to negotiate the purchase of vaccines on behalf of the member states, agreed to send him three documents (an email, a letter and a press release), but none of the SMS.
The EC argued that it did not keep the SMS, because there is no such obligation, as they are not subject to the transparency rules dating from 2001 of the European institutions.
Early this year, the European ombudsman, Emily O’Reilly, reproached the European Commission for refusing to give information to the press about the exchange of text messages between the chief executive of the EU, Ursula von der Leyen, and the chief executive of the Pfizer company, Albert Bourla, on the subject of the purchase of vaccines against COVID-19.
Another scandal broke out in Italy because the funds of the National Recovery and Resilience Plan (PNRR) deriving from Next Generation EU funding ended up in a research project on mRNA vaccines of the University of Padua in which Pfizer, Astrazeneca, Biontech also participate alongside Orgenesis, the American pharmaceutical company in which Heiko Von der Leyen, husband of the President of the EU Commission Ursula, is medical director.
On the cover image EU Commission President Ursula Von der Leyen embraces Pfizer CEO Albert Bourla
Join: 👉 https://t.me/acnewspatriots
The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of AC.NEWS
Disclaimer: This article may contain statements that reflect the opinion of the author. The contents of this article are of sole responsibility of the author(s). AC.News will not be responsible for any inaccurate or incorrect statement in this article www.ac.news websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner. Reprinting this article: Non-commercial use OK. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
Discussion about this post